Eusol Biotech Co., Ltd.

Eusol Biotech Co., Ltd. is a biotechnology company specializing in the research and development of pharmaceuticals, with a primary focus on novel biotech drugs targeting neurological and sleep-related disorders. Established in 1994 and headquartered in Taipei, Taiwan, Eusol Biotech’s core activities include the development of innovative therapeutics such as ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) designed for neural repair, and SM-1, a composite capsule formulated from three commercially available sedative drugs aimed at addressing sleep dysfunction. Operating within the healthcare sector, the company leverages advanced biotechnological methods to advance treatments that address unmet medical needs in neurology and psychiatry. Eusol Biotech plays a role in Taiwan’s pharmaceutical landscape by driving forward early-stage drug discovery efforts, particularly for sleep and neurological conditions, although it remains a smaller player compared to larger regional biotech firms. The company’s activities contribute to the broader pharmaceutical and biotech sector by providing a research-focused approach to novel drug development, positioning itself in niche but medically significant segments of the market.